Search the Newsreel

Enterprise value to EBITDA forward of Alaunos Therapeutics, Inc. – NASDAQ:TCRT

This article provides the enterprise value to EBITDA forward for Alaunos Therapeutics, Inc. (NASDAQ: TCRT). It is a financial data point presented by TradingView, indicating a specific valuation metric for the biotechnology company. The content appears to be a financial data page rather than …

Enterprise value to EBIT forward of Alaunos Therapeutics, Inc. – NASDAQ:TCRT

This article provides a brief financial snippet for Alaunos Therapeutics, Inc. (NASDAQ: TCRT), focusing on its enterprise value to EBIT forward metric. The content itself is very minimal, essentially a placeholder or header indicating where detailed financial information would typically be presented on the …

Alaunos Therapeutics Inc (TCRT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey provides a revenue breakdown for Alaunos Therapeutics Inc (TCRT). It notes that relevant data regarding business segments, regional revenue, and profit contribution have not yet been disclosed by the company. The page also displays the current stock price and market …

Alaunos Therapeutics Inc (TCRT) Financial Health: Profitability & Balance Sheet Analysis

Alaunos Therapeutics Inc (TCRT) has a current financial score of 7.34, ranking 128th out of 384 in the Biotechnology & Medical Research industry, indicating robust financial status but low operating efficiency. Its latest quarterly revenue saw a 100.00% year-over-year decrease, and net profit decreased …

CEO Holger Weis takes Alaunos Therapeutics, Inc. (TCRT) stock instead of salary

Alaunos Therapeutics, Inc. CEO Holger Weis received a grant of 4,568 common stock shares on July 23, 2026, priced at $1.92 per share, as compensation in lieu of his net salary. Following this transaction, Weis directly holds 21,120 common shares. This move is categorized …

Alaunos Therapeutics, Inc. (TCRT) director receives 8,138-share board fee grant

Alaunos Therapeutics director Michael Allen Jerman received a grant of 8,138 shares of common stock on July 23, 2026, valued at $1.92 per share, in lieu of board fees. This transaction increased his direct holdings to 23,759 shares. The Form 4 filing details the …

Alaunos Therapeutics (TCRT) director gets 8,789-share equity grant in lieu of fees

Alaunos Therapeutics director Jaime Vieser received an equity grant of 8,789 shares of common stock valued at $1.92 per share, issued in lieu of board fees on July 23, 2026. This grant increased his direct holdings to 47,642 shares, with additional indirect holdings through …

Alaunos Therapeutics (TCRT) director granted 8,463 shares for board fees

Robert W. Postma, a director at Alaunos Therapeutics, Inc. (TCRT), received 8,463 shares of common stock on July 23, 2026, valued at $1.92 per share, as compensation for board fees. This transaction increased his direct holdings to 58,609 shares, with additional indirect holdings through …

Alaunos Therapeutics Inc (TCRT) Cash Flow

This article provides the cash flow statement for Alaunos Therapeutics Inc (TCRT), including quarterly and annual data for operating, investing, and financing activities. It details various components such as net income, capital expenditures, and changes in working capital over several fiscal years. The article …

Alaunos Therapeutics Inc (TCRT) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Alaunos Therapeutics Inc's (TCRT) dividend history and stock split events. The company has not distributed any dividends in the past five years. However, it has undergone several merger-related stock splits in July 2024 and January 2024.

Alaunos Therapeutics, Inc. Revenue Breakdown – NASDAQ:TCRT

This article provides a revenue breakdown for Alaunos Therapeutics, Inc. (NASDAQ: TCRT), highlighting that the greatest contribution to its revenue came from the United States, with reported figures of $5,000 USD last year and $10,000 USD the year prior. The revenue is categorized by …

TCRT|Alaunos Therapeutics Inc|Price:1.940|Chg%:-0.040

This article provides a detailed stock score analysis for Alaunos Therapeutics Inc (TCRT) by TradingKey, indicating healthy fundamentals and high growth potential, despite a recent weak market performance. The valuation is considered fairly valued within the Biotechnology & Medical Research industry, with high institutional …

Alaunos Therapeutics Inc (TCRT) Institutional Confidence

This article from TradingKey provides an overview of Alaunos Therapeutics Inc's (TCRT) institutional confidence, showing key shareholder activity and holdings. It lists several institutional investors and individuals, along with their share amounts and percentage changes. The stock closed at $1.940, down 2.08%, as of …

Price to earnings forward of Alaunos Therapeutics, Inc. – NASDAQ:TCRT

The article references the price to earnings forward of Alaunos Therapeutics, Inc. under the NASDAQ:TCRT ticker. It appears to be a financial data page from TradingView, indicating that the market for TCRT was closed with no trades. The content primarily consists of navigation and …

Enterprise value to revenue forward of Alaunos Therapeutics, Inc. – NASDAQ:TCRT

This article provides an enterprise value to revenue forward metric for Alaunos Therapeutics, Inc. (NASDAQ: TCRT). It focuses on financial data for the company, accessible through TradingView, and does not contain detailed analysis or news content. The piece appears to be a stub or …

TCRT Q4 2023 Earnings: Alaunos Therapeutics Misses EPS Expectations, Stock Declines as Pipeline Progress Remains Key - Investor Earnings Call

Alaunos Therapeutics Faces Nasdaq Non-Compliance, Delisting Risk

Alaunos Therapeutics, Inc. Financial Statements – NASDAQ:TCRT